An interventional study of Avastin and Avastin in Exudative Macular Degeneration and Diabetic Macular Edema, sponsored by Vitreo-Retinal Associates, Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-12-17.
Sponsored by Vitreo-Retinal Associates, Michigan · Not applicable, Interventional, and Health services research
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
233 studies on the registry are indexed under Wet Macular Degeneration; 19 are open to participants now.
This study's enrollment of 16 is below the median of 56 across 182 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Vitreo-Retinal Associates, Michigan is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1.25 mg avastin monthly for 4 months
Drug: Avastin
1.25 mg Avastin monthly for 4 months
Drug: Avastin
0.5 mg Lucentis monthly for 4 months
Drug: Lucentis
Analysis of collected vitreous samples to identify biomarkers.
Analysis of collected vitreous samples in regards to identification of biomarkers that are prognostic for response to anti-angiogenic treatment of retinopathy, and the exploration of a more effective dosing regiment for intravitreal injections of Lucentis/Avastin for exudative macular degeneration and Avastin for diabetic macular edema.
Time frame: End of study
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Ranibizumab
Vitreo-Retinal Associates, Michigan